After Italy, Curaleaf obtains license for medicinal products based on cannabis extracts in Malta

Curaleaf International has licensed a line of cannabis extract-based medicines in Malta. The product range is being manufactured to meet the growing demand for high quality medical cannabis products across Europe and follows on from Curaleaf being the first company to register a cannabis extract active pharmaceutical ingredient (API). with THC in Italy. The products are already being prescribed to patients in the UK and Germany, the company announced in Press release.

Curaleaf's line of licensed cannabis-based medicines incorporate a variety of different concentrations and formulations of THC/CBD in oil form that will meet a wide range of specialist requirements, all 100% European in origin, from plant to processing and certified with EU-GMP through the company of vertically integrated businesses.

Antonio Costanzo, CEO of Curaleaf International, said, “We are very proud of this achievement. Thanks to Curaleaf International's regulatory expertise in pharmaceuticals, we have gained the registration of a full line of medicines to meet the demand of physicians, pharmacists and patients for high quality cannabis products in the future. We believe this will open up a new era of opportunities for licensed cannabis-based medicines on the Maltese market. This news, in addition to our recent registration in Italy, is a very promising moment for Curaleaf International as we continue to witness growing demand for our products across the growing European market.”

Commenting on Curaleaf International's broader research strategy, Barbara Pacchetti, Chief Scientific Officer said, “Curaleaf International is committed to advancing the industry's understanding of the medical potential of cannabis through licensed cannabis-based medicines. We envision a new era of placing cannabis-based medicine in disease treatment protocols alongside conventional substances. Our scientific research and pioneering clinical programs are designed to provide more clinical data to support the growing medical cannabis market. Our aim is to continue to build evidence on the potential therapeutic benefits of medical cannabis for patients and clinicians,” she concluded.